loading...
Distributed by Mapi Research Trust
Distributed by Mapi Research Trust
Sanofi Aventis
All
Gater A, Reaney M, Findley A, Brun-Strang C, Burrows K, Nguyên-Pascal ML, Roborel de Climens A. Development and First Use of the Patient's Qualitative Assessment of Treatment (PQAT) Questionnaire in Type 2 Diabetes Mellitus to Explore Individualised Benefit-Harm of Drugs Received During Clinical Studies. Drug Saf. 2020 Feb;43(2):119-134. (PubMed abstract)
Adam Gater, Matthew Reaney, Amy Findley, Catherine Brun-Strang, Kate Burrows, My-Liên Nguyên-Pascal and Aude Roborel de Climens. Tell me more: Exploring patient perspective on the benefits and disadvantages of drugs during clinical trials. #84209, DIA San Diego, USA, 2019 (Poster).
Sanofi Aventis
Mapi Research Trust
PROVIDE™
27 rue de la Villette
69003 Lyon
France
Phone: +33 (0)4 72 13 66 66
You may access the questionnaire and/or its available translations directly (see tutorial). Should you not see the Download button, please contact us.
Fees may apply to your project. Submit your request (see tutorial). Our PROVIDE team will get back to you with the needed information and license agreement in a timely manner.
Examination copies can only be used for the limited purpose of examining the suitability of the Questionnaire for subsequent research and/or clinical use, and cannot be used in research or in clinical practice or distributed to others.
You are not authorized to modify, retype, translate, copy or otherwise duplicate the Questionnaire except with the further and prior written permission of Mapi Research Trust / the developers / copyright holders / distributors.
The list of available translations is subject to constant changes and may not be exhaustive. It is provided for information only. Some recently produced translations may not be included in the list below yet. Please do check the status of available translations with Mapi Research Trust / the developers / copyright holders / distributors.
Also, the listed translations may not have undergone a full linguistic validation process and may require further work to be suitable for use in a study.
The author has selected Mapi/ICON Language Services as exclusive linguistic validation company to ensure the production of harmonized and consistent language versions.
For additional information on available translations of this instrument, or for a project involving new languages, please submit a request (tutorials available on our FAQs).
Access to advanced descriptions of Clinical Outcome Assessments (COAs)